One of these, PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe), conducted primarily in Germany, reported a 29.1% rate of change in treatment recommendation and rates of physician adherence to 70-GS risk assessment of 92.3% in 70-GS Low Risk and 94.3% in 70-GS High Risk cases [14, 16], similar to reported rates in the current study. This evidence concerns the gene NR4A1 and breast cancer.